Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.
Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms. Patients receiving these agents are at risk of acute or subacute pulmonary damage. The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 docetaxel who developed subacute interstitial pneumonitis-related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment. Even though only a few cases of this adverse event have been reported in the literature, severe docetaxel-induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms.
Leimgruber
Karl
K
Departments of Internal Medicine,S. Maurizio Central Hospital of Bolzano, Bolzano, Italy.
Negro
Rosa
R
Baier
Susanne
S
Moser
Bernadetta
B
Resch
Gerhard
G
Sansone
Stefano
S
Adami
Michele
M
Zanon
Peter
P
Graiff
Claudio
C
Egarter-Vigl
Eduard
E
Wiedermann
Christian J
CJ
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077143:Docetaxel; D017809:Fatal Outcome; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel